Patient preference and tolerability of a DPP-4 inhibitor a GLP-1 analog in patients with type 2 diabetes mellitus inadequately controlled with metformin: a 24-week, randomized, multicenter, crossover study

Autor: Jörg Lüdemann, Eva D. Dütting, Markus Dworak

Publikováno v: Therapeutic Advances in Endocrinology and Metabolism, Vol 6 (2015)

Objective: The present study aimed to assess the patient preference and tolerability of oral dipeptidyl peptidase-4 inhibitor (vildagliptin) versus injectable glucagon-like peptide-1 analog (liraglutide) in patients with type 2 diabetes mellitus inad

Externí odkaz: https://doaj.org/article/d2b02315b94f4434a854a6793f1b4f97

Myocardial metabolism in heart failure: Purinergic signalling and other metabolic concepts

Autor: Tobias Merkel, Markus Dworak, Geoffrey Burnstock, Andreas L. Birkenfeld, Jens Jordan

Publikováno v: Pharmacol. Ther. 194, 132-144 (2019)
Birkenfeld, A L, Jordan, J, Dworak, M, Merkel, T & Burnstock, G 2018, ' Myocardial metbolism in heart failure : Purinergic signalling and other metabolic concepts ', Pharmacology and Therapeutics . https://doi.org/10.1016/j.pharmthera.2018.08.015

Despite significant therapeutic advances in heart failure (HF) therapy, the morbidity and mortality associated with this disease remains unacceptably high. The concept of metabolic dysfunction as an important underlying mechanism in HF is well establ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4d7e7060b8b85eb26b415c4862cb055
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=54191

Early insights into the characteristics and evolution of clinical parameters in a cohort of patients prescribed sacubitril/valsartan in Germany

Autor: Sara Bruce Wirta, B. Balas, Raymond G. Schlienger, D. Viriato, F Calado, Catia C Proenca, Rolf Wachter, Stefanie S Grunow, J. Engelhard, Markus Dworak, Sven Klebs, Matthias Schindler

Publikováno v: Postgraduate medicine. 130(3)

This study aimed to provide early insights into sacubitril/valsartan (sac/val) prescription patterns and the demographic and clinical characteristics of patients prescribed sac/val in primary care and cardiology settings in Germany.The study used ele

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbe14d5748d0e62451e298ab3400256d
https://pubmed.ncbi.nlm.nih.gov/29446691

P4395Characteristics of patients with heart failure prescribed sacubitril/valsartan in the primary care setting in Germany

Autor: Sven Klebs, F Calado, B. Balas, Catia C Proenca, Matthias Schindler, Raymond G. Schlienger, Stefanie S Grunow, J. Engelhard, Markus Dworak, S. Bruce Wirta

Publikováno v: European Heart Journal. 38

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7ebc56568421fc4838295370f972308e
https://doi.org/10.1093/eurheartj/ehx504.p4395

Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?

Autor: James E. Foley, Q. Shao, Bo Ahrén, Markus Dworak, Guenter Heimann, Anja Schweizer, Mouna Akacha, Sylvie Dejager

Publikováno v: Diabetes Therapy
Diabetes therapy : research, treatment and education of diabetes and related disorders; (2014)

Introduction In a previously published study, vildagliptin showed a reduced risk of hypoglycemia versus glimepiride as add-on therapy to metformin at similar efficacy. Glimepiride was titrated from a starting dose of 2 mg/day to a maximum dose of 6 m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83cb85b03257d608c385b8224a277f57
http://europepmc.org/articles/PMC4269641